
- February 2024
- Volume 30
- Issue 2
- Pages: SP113
NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer
The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing tumors.
Mirvetuximab soravtansine (Elahere; Immunogen) plus bevacizumab was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a 2B recommendation for patients with platinum-sensitive
The regimen was first added to the NCCN Clinical Practice Guidelines in Oncology as a category 2B recommendation for platinum-resistant disease expressing FRα. The change to category 2A from 2B indicates uniform NCCN panel consensus that the intervention is appropriate vs simply consensus.
The FDA granted
Mirvetuximab soravtansine in combination with bevacizumab has been shown active and well-tolerated, with findings
As a single agent, mirvetuximab soravtansine is a category 2A preferred regimen for platinum-resistant disease with tumors expressing FRα.1
Positive results from the confirmatory MIRASOL trial were
The full MIRASOL results, published in the
Other updates in the new guidelines related to recurrence therapy for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer included the addition of oral cyclophosphamide, pembrolizumab, and bevacizumab as a category 2A regimen in the “other recommended regimens” category; as well as fam-trastuzumab deruxtecan-nxki as a category 2A recommendation for HER2-positive tumors (immunohistochemistry result of 3+ or 2+).1
References
1. NCCN. Clinical Practice Guidelines in Oncology. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, version 1.2024. Accessed January 19, 2024.
2. Joszt L. FDA approves mirvetuximab soravtansine-gynx for platinum-resistant ovarian cancer. AJMC. November 15, 2022. Accessed January 19, 2024. https://www.ajmc.com/view/fda-approves-mirvetuximab-soravtansine-gynx-for-platinum-resistant-ovarian-cancer
3. Gilbert L, Oaknin A, Matulonis UA, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241-247. doi:10.1016/j.ygyno.2023.01.020
4. Caffrey M. MIRASOL: Mirvetuximab soravtansine Improves PFS, OS in certain women with recurrent ovarian cancer. AJMC. June 4, 2023. Accessed January 19, 2024. https://www.ajmc.com/view/mirasol-mirvetuximab-soravtansine-improves-pfs-os-in-certain-women-with-recurrent-ovarian-cancer
5. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162-2174. doi:10.1056/NEJMoa2309169
Articles in this issue
over 1 year ago
The Socratic Method May Save Health Careover 1 year ago
Center on Health Equity and Access: February 2024over 1 year ago
Scaling Palliative Care Requires Adherence to Best PracticesNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.